

Claire Chaussade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12199461/publications.pdf>

Version: 2024-02-01

18
papers

904
citations

623734

14
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

1390
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. <i>Biochemical Journal</i> , 2007, 404, 449-458.	3.7	188
2	Production of Phosphatidylinositol 5-Phosphate by the Phosphoinositide 3-Phosphatase Myotubularin in Mammalian Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 7304-7312.	3.4	127
3	Expression of Myotubularin by an Adenoviral Vector Demonstrates Its Function as a Phosphatidylinositol 3-Phosphate [PtdIns(3)P] Phosphatase in Muscle Cell Lines: Involvement of PtdIns(3)P in Insulin-Stimulated Glucose Transport. <i>Molecular Endocrinology</i> , 2003, 17, 2448-2460.	3.7	75
4	Inactivation of the Class II PI3K-C2 β Potentiates Insulin Signaling and Sensitivity. <i>Cell Reports</i> , 2015, 13, 1881-1894.	6.4	66
5	Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. <i>Nature Communications</i> , 2017, 8, 1804.	12.8	59
6	Essential role of class II PI3K-C2 β in platelet membrane morphology. <i>Blood</i> , 2015, 126, 1128-1137.	1.4	52
7	Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110 β inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 7677-7687.	3.0	51
8	Functional differences between two classes of oncogenic mutation in the PIK3CA gene. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 577-581.	2.1	50
9	Nuclear Forkhead Box O1 Controls and Integrates Key Signaling Pathways in Hepatocytes. <i>Endocrinology</i> , 2007, 148, 2424-2434.	2.8	39
10	Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16217-16222.	7.1	36
11	Novel pyrazolo[1,5-a]pyridines as p110 β -selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 58-68.	3.0	34
12	Discovery of pyrazolo[1,5-a]pyridines as p110 β -selective PI3 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 69-85.	3.0	30
13	Phosphoinositide-3-kinase (PI3K) inhibitors: Identification of new scaffolds using virtual screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5842-5847.	2.2	27
14	Inactivation of class II PI3K-C2 β induces leptin resistance, age-dependent insulin resistance and obesity in male mice. <i>Diabetologia</i> , 2016, 59, 1503-1512.	6.3	23
15	Investigating the role of class-IA PI 3-kinase isoforms in adipocyte differentiation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 379, 830-834.	2.1	15
16	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. <i>MedChemComm</i> , 2014, 5, 41-46.	3.4	12
17	Evidence for a role for the p110 β isoform of PI3K in skeletal function. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 564-569.	2.1	11
18	Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110 β -selective PI3 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 187-190.	2.2	9